Cargando…
Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236440/ https://www.ncbi.nlm.nih.gov/pubmed/29455687 http://dx.doi.org/10.1017/S003329171800017X |
_version_ | 1783371034106265600 |
---|---|
author | Fernandez-Egea, Emilio Worbe, Yulia Bernardo, Miguel Robbins, Trevor W. |
author_facet | Fernandez-Egea, Emilio Worbe, Yulia Bernardo, Miguel Robbins, Trevor W. |
author_sort | Fernandez-Egea, Emilio |
collection | PubMed |
description | BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. RESULTS: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. CONCLUSIONS: Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients. |
format | Online Article Text |
id | pubmed-6236440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62364402018-11-19 Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia Fernandez-Egea, Emilio Worbe, Yulia Bernardo, Miguel Robbins, Trevor W. Psychol Med Original Articles BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. RESULTS: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. CONCLUSIONS: Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients. Cambridge University Press 2018-12 2018-02-19 /pmc/articles/PMC6236440/ /pubmed/29455687 http://dx.doi.org/10.1017/S003329171800017X Text en © Cambridge University Press 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Fernandez-Egea, Emilio Worbe, Yulia Bernardo, Miguel Robbins, Trevor W. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title | Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title_full | Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title_fullStr | Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title_full_unstemmed | Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title_short | Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
title_sort | distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236440/ https://www.ncbi.nlm.nih.gov/pubmed/29455687 http://dx.doi.org/10.1017/S003329171800017X |
work_keys_str_mv | AT fernandezegeaemilio distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia AT worbeyulia distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia AT bernardomiguel distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia AT robbinstrevorw distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia |